Flavonoids are known to have anxiolytic and sedative effects mediated via actions on ionotropic GABA receptors. We sought to investigate this further.
Introduction
GABAA receptors not only mediate fast synaptic inhibition in the mammalian brain, but also participate in the regulation of the resting potential of neurons by activating tonic currents in extrasynaptic locations of neurons (Farrant and Nusser, 2005) . Therefore, it is not surprising that these receptors are implicated in a variety of neuropsychiatric disorders including anxiety, sleep, cognitive and mood disorders, epilepsies and schizophrenia (Olsen and Sieghart, 2009) .
GABAA receptors are members of the cys-loop family of receptors and form a central chloride ion channel from five homologous subunits. Each subunit contains a large aminoterminal extracellular domain, four transmembrane domains from M1 to M4 and a large intracellular domain between M3 and M4 (Sieghart, 2006) . Within the GABAA receptor class, there exists a great deal of receptor heterogeneity, as different protein subunits (including a1-6, b1-3, g1-3, d ) can assemble in various combinations. Receptor heterogeneity exists in vivo, with a1-containing and a2/3-containing isoforms being the most common subunit combinations. These receptors are believed to exist in a 2:2:1 stoichiometry in vivo (McKernan and Whiting, 1996) . The subunit composition determines the GABA sensitivity, the pharmacological properties of the GABAA receptor (Olsen and Sieghart, 2009 ) and the receptor interaction partners mediated by the larger intracellular loop between M3 and M4 (Tierney, 2011) .
A number of clinically important drugs including benzodiazepines, neurosteroids, barbiturates, general anaesthetics such as propofol, etomidate and volatile anaesthetics act as positive allosteric modulators of this receptor (Olsen and Sieghart, 2009 ). Many of these agents possess dual effects, also directly activating GABAA receptors at high concentrations (Orser et al., 1994) .
The a1-containing GABAA have been proposed to be responsible for the sedative action of benzodiazepines; the a2 and/or the a3 subtypes have been suggested to mediate the anxiolytic activity and the myorelaxation effects, whereas the a5 subtype has been associated with cognition processes. Given the heterogeneous nature and complex pharmacology of GABAA receptors, it is therefore important to develop subtype-specific ligands with potentially fewer side effects (Rudolph et al., 1999) .
Flavonoids are characterized by a phenylbenzopyran chemical structure. They are secondary plant metabolites that are consumed by humans in significant amounts from beverages, fruits and vegetables (Mattila et al., 2000) . Such compounds are reported to have significant health benefits being involved in a variety of biological processes. Recently, flavonoids such as 6-methylflavone (Hall et al., 2004) , 6-methylflavanone (Hall et al., 2005) , 6-hydroxyflavone (Ren et al., 2010) and 6,2'dihydroxyflavone (Wang et al., 2007) have also been shown to modulate GABAA receptors. As flavonoids can vary in activity and function, the development of subtype-selective ligands based on the flavonoid core structure may lead to selective treatment of GABA systemassociated pathology (Hanrahan et al., 2011; Jager and Saaby, 2011; Nilsson and Sterner, 2011) .
Of particular interest are the synthetic flavonoids, 6-methylflavone and 6-methylflavanone, which acted as flumazenil-insensitive positive modulators of recombinant GABA A receptors expressed in oocyctes (Hall et al., 2004; . In the case of 6-methylflavanone it was shown that subtype selectivity for a2-over a1-containing GABAA receptors in terms of relative efficacy could be achieved (Hall et al., 2005) . Indeed targeting specific GABAA receptors through subtype-selective efficacy as distinct from potency has been validated for other modulators of GABAA receptors, including the non-sedating anxiolytic, 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1, 2,4-triazolo [4,3-b] pyridazine (TPA023) and the cognitive enhancer, alpha 5IA [3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo [3,4-a] phthalazine] (Atack, 2010a,b) .
In the present study, we examined the actions of an analogue of 6-methylflavone, 2′methoxy-6-methylflavone (2′MeO6MF) on human recombinant a1-3,5b1-3g2L and a1/2b2 GABAA receptors expressed in Xenopus oocytes and on native GABAA receptors in rat newborn hippocampal patches that express multiple receptor subtypes . In this study, we report that 2′MeO6MF positively modulates a1b1-3g2L GABAA receptors, whereas at a2b2/3g2L GABAA receptors, the flavonoid directly activates these receptors in the absence of GABA. In contrast, 2′MeO6MF positively modulates a2b1g2L GABAA receptors. The 15′ residue located at the extracellular end of the second transmembrane domain of the b-subunit was found to be important in determining activation versus modulatory effects for a2-containing GABAA receptors. As 2′MeO6MF showed direct and modulatory effects on a1/2 containing GABAA receptors we evaluated its effects in mouse models of sedation and anxiety.
Methods

Drugs
GABA, bicuculline, gabazine, flumazenil and DMSO were purchased from Sigma (St. Louis, MO, USA), whereas diazepam was purchased from Apin Chemicals LTD (Oxon, UK). -1 ) were obtained from Perkin Elmer (Boston, MA, USA). Pentylenetetrazole (PTZ) was purchased from Tocris Biosciences (Bristol, UK). 2′MeO6MF was synthesized according to Supporting Information Scheme 1 and briefly described in the following.
The synthesis of 2′MeO6MF is depicted in Scheme 1 (Supporting Information). The synthesis involves one-step modified Schotten-Baumann reaction, and a Baker-Venkataraman rearrangement followed by acid catalysed cyclization. Substituted 2-hydroxydibenzoyl methane I was prepared in one-step from 2-hydroxy-5-methyl acetophenone and 2-methoxybenzoyl chloride in the presence of lithium diisopropylamide. Intermediate I was further cyclized in the presence of glacial acetic acid and concentrated H2SO4 at 120°C to produce the crude product. The crude product was purified by flash chromatography, treated with activated charcoal, filtered through celite and recrystallized twice from acetone to produce 2′MeO6MF (Ն98% by NMR and elemental analysis). The assigned structure was in agreement with the 1 H (400 MHz) and 13 C (100.5 MHz) NMR spectra. Further details concerning synthesis, analytical and spectral characterization data are given in Supporting Information. 
Animal use
GABA receptor subunit constructs
Human a1, a2, b2 and g2L DNA in pcDM8 were provided by Dr Paul Whiting (Merck, Sharpe and Dohme Research Labs, Harlow, UK), a3 and b3 in pGEMHE, a5 in pcDNA3 and b1 in PCDM8 were a gift from Dr Bjarke Ebert (H. Lundbeck A/S, Valby, Denmark). Human r1 DNA in pCDNA1.1 was provided by Dr George Uhl (National Institute for Drug Abuse, Baltimore, MD, USA).
Site-specific mutations were introduced into the cDNAs of the GABA A receptor subunits using QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Mutant clones were submitted to complete sequencing to corroborate the successful incorporation of the point mutation and absence of spurious mutations.
cDNA vectors were linearized with the appropriate restriction endonucleases and capped transcripts were produced from linearized plasmids using the 'mMessage mMachine' T7 transcript kit from Ambion (Austin, TX, USA).
Expression of recombinant GABA receptors in Xenopus oocytes
The procedures involving the use of female Xenopus laevis were carried out according to previously described protocols (Hall et al., 2004) and were approved by the Animal Ethics Committee of the University of Sydney. In brief, female Xenopus laevis were anaesthetized by immersion in 0.17% 3-aminobenzoic acid ethyl ester with 0.02% NaCl for 10-15 min, and a lobe of the ovaries was surgically removed. The lobe was rinsed with oocyte releasing buffer 2 (OR2) (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2, 5 mM HEPES, pH 7.5) and treated with collagenase A (2 mg·mL -1 in OR2, Bohringer Mannheim, Germany) for 1-2 h to separate oocytes from connective tissue and follicular cells. Released oocytes were rinsed in ND96 'wash' solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5). Stages V-VI oocytes were collected and kept at 18°C in ND96 'storage' solution (ND96 'wash' solution supplemented with 2.5 mM pyruvate, 0.5 mM theophylline and 50 mg·mL -1 gentamycin).
Oocytes were injected with mRNA in the ratio 1:1:10 (5:5:50 ng) for a1-3,5b1-3g2L to favour incorporation of the g subunit (Boileau et al., 2002) , 1:1 for a1/2b2 and r1 (40-60 ng 50 nL -1 ) before storing at 18°C. Sham-injected oocytes were prepared by injection with nuclease-free water.
Two to five days after injection of RNA, receptor activity was measured by two-electrode voltage clamp recording as previously reported (Hall et al., 2004) . In recordings using the flavonoid 2′MeO6MF the DMSO concentration in the perfusate was 0.8% and did not produce any alteration in the recordings.
Oocytes expressing a1-3,5b1-3g2L GABA A receptors were screened with 10 mM Zn 2+ in the presence of two concentrations of GABA (10 and 100 mM) to ensure that the g2L subunit was incorporated. GABA A receptors without a g2L-subunit are sensitive to inhibition by Zn 2+ , whereas those expressing a g2L subunit are not (Hosie et al., 2003) .
Data analysis
The currents elicited directly by 2′MeO6MF were normalized as I%(comp) = [Icomp/IMAX(GABA)] ¥ 100, where Icomp is the peak amplitude of the current produced by 2′MeO6MF and IMAX(GABA) is the maximal current produced by GABA measured in each individual cell.
The enhancement effects of 2′MeO6MF were measured in the presence of a GABA concentration eliciting between 7 and 10% of the maximal current amplitude (EC 7-10). The EC7-10 was determined at the beginning of each experiment. Enhancement of the chloride current was defined as % potentiation = [(Idrug+GABA-IGABA)/IGABA]100 where Idrug+GABA is the control GABA current in the presence of a given concentration of drug, and IGABA is the control GABA current. In all cases, a 4-6 min washout period was allowed between drug applications to avoid receptor desensitization.
Standardized responses were plotted against drug concentration on a semi-logarithmic scale using Prism v5 GraphPad software, San Diego, CA, USA. Logarithmically transformed data were tested for significance using a linear regression fit. Provided the slope of the curve significantly deviated from zero, a nonlinear regression fit was performed using a sigmoidal dose-response (variable slope), the equation of which is 
Neuronal cell culture and electrophysiology
Newborn rat hippocampal neurons were dissociated from Wistar rats and maintained in culture as described previously (Curmi et al., 1993) . Single-channel recordings in the insideout configuration were acquired after 7-15 days. The external solution contained (mM): 135 NaCl, 3 KCl, 2 CaCl 2, 5 MgCl2 and 10 TES (pH 7.3). Patch electrodes contained (mM): 138 choline chloride, 0.3 KCl, 7 MgCl2, 10 TES (pH 7.3). Peptides were dissolved in DMSO (final concentration Յ 0.01%), diluted to the required concentration with external solution and applied to the patch by exposing the pipette tip to flow tubes containing the test solutions Binding studies Membrane preparations. All binding assays were performed using rat brain synaptic membranes of the cortex and central hemispheres from adult male Wistar rats with tissue preparations, as described previously (Ransom and Stec, 1988) . On the day of the assay, the membrane preparation was quickly thawed, suspended in 40 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) using an UltraTurax homogenizer (IKA, Wilmington, NC, USA), and centrifuged at 48 000¥ g for 10 min at 4°C. This washing step was repeated four times. The final pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) for the binding assay.
Binding assays.
Membranes (100 ng of protein/aliquot) in Tris-HCl buffer (50 mM, pH 7.4) were incubated with either [
3 H]-muscimol (5 nM) and GABA (1 mM) or [ 3 H]-flunitrazepam and diazepam (10 mM) at 0°C for 60 min in a total volume of 250 mL. GABA (1 mM) and diazepam (10 mM) were used to determine non-specific binding. The binding reaction was terminated by rapid filtration through GF/C unifilters (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) using a 24 channel cell harvester (Brandel, Gaithersburg, MD, USA) followed by washing with 3 ¥ 250 mL of ice-cold binding buffer. ULTIMA-GOLD liquid scintillation cocktail (Perkin Elmer) was added to the dried filters, and the amount of filter-bound radioactivity was quantified in a Packard Top Count microplate scintillation counter (Perkin Elmer Life and Analytical Sciences). Data are expressed as percentage of control specific binding. EC50 values are expressed as mean Ϯ SEM.
In vivo studies Animals. All behavioural tests were performed on male Balb-c mice (Animal Resources Centre, Perth, Australia) aged 8-10 weeks, weighing 25-35 g. Animals were housed in groups of four per cage with free access to food and water, and maintained in a controlled environment (20-23°C, 45 -55% relative humidity) with a 12/12 h light/dark cycle (light on at 0600 h). Illumination of the experimental room was 80 lux. Drugs were dissolved in the vehicle comprising of DMSO (5%), Tween 80 (1%) and saline (94%), and administered by i.p. injection in a volume of 5 mL·g -1
. Sodium thiopental was dissolved in saline. All behavioural studies were carried out between 0900 and 1400 h.
General behavioural and acute toxicity tests in mice
The overt behavioural effects of 2′MeO6MF on mice after i.p. injection were assessed using the protocol detailed by Irwin (Irwin, 1968) and elsewhere (Chebib et al., 2009) . In brief, animal tails were marked with waterproof markers to assign them to one of four groups each consisting of five animals for random blind allocation to one of four experimental conditions: vehicle; test dose 1; test dose 2; and test dose 3, which were 1, 10 and 100 mg·kg -1 . Observations were recorded pertaining to the following parameters: spontaneous activity; exophthalmics; piloerection; aggressiveness; writhing; tremors; clonic convulsions; tonic convulsions; gasping; hypersensitivity; docility; position struggle; salivation; cyanosis; vasoconstriction; vasodilatation; finger approach; finger escape; hind limb placing; ataxia; hyperesthesia; Straub tail; visual placing; tail pinch; righting reflex; catalepsy; bizarre behaviour; prehensile strength; and pupil size, according to the procedure prescribed by Irwin (Irwin; 1968) . Animals were injected with vehicle or drugs, and 20 min later placed in the centre of the apparatus facing an open arm and allowed to explore the maze for 5 min. An arm entry was defined by having all four paws inside the arm. All sessions were videotaped with a digital camera positioned above the maze and at the end of the test behavioural parameters were scored by the experimenter from observing the videos. To assess the involvement of the GABAergic system, animals were either pretreated i.p. with vehicle, flumazenil or PTZ. After individual trials, the apparatus was carefully cleaned with wet paper towel (mixture of ethanol, detergent and water) to remove any residue or odours. The % of open-arm entries and the % of time spent in the open arms were recorded as a measure of anxiety state (File and Pellow, 1985) . The absolute number of closed arm entries was also recorded to assess effects on general locomotor activity.
Elevated plus maze
Measurement of locomotor activity
Immediately after completing the plus maze assay, animals were placed in a box made of clear Plexiglas, with a floor of 30 ¥ 15 cm and 15 cm high walls, which possesses 15 optical beams, which allows the measure of animal activity along a single axis of motion (Fernandez et al., 2008) . Spontaneous locomotor activity was measured for 5 min and expressed as total number of light beams crossed.
Holeboard assay
This assay was conducted in an automatic apparatus described previously (Fernandez et al., 2008) . Twenty minutes after injection with vehicle or the drug, animals were placed in the centre of the board and allowed to freely explore the arena for 5 min. The number and duration of head dips were recorded. After each trial the apparatus was wiped clean to remove traces of the previous assay. A decrease in the number of head dips and/or the time spent head dipping is associated with a sedative effect (File and Pellow, 1985) .
Light/dark box test
The light/dark apparatus consists of an acrylic box of dimensions 44 ¥ 21 ¥ 21 cm, divided into a small dark compartment (one-third) and a large illuminated compartment (twothirds), the division between zones contains an opening of 6 ¥ 3 cm. The box possesses 16 light beams, 11 in the lit area and five in the dark area, which detect the movement of the animal. The box is connected to a computer that records the number of transitions between areas, latency to the first transition, time and activity in each zone and total activity in a 5 min session. An increase in the exploration of the lit area is associated with an anxiolytic effect; as such, two parameters were selected as a measure of anxiety: the time spent in the lit compartment and the total number of transitions (Bourin and Hascoet, 2003) .
Thiopental-induced loss of righting reflex
A sub-threshold dose of sodium thiopental (40 mg·kg -1 ) was injected i.p. into mice 20 min after a similar injection of vehicle or drugs. The duration of the loss of the righting reflex was recorded (Ferrini et al., 1974) .
Horizontal wire test
Animals were trained in two separate sessions the day before. On the day of the assay, animals were injected with vehicle or drug and the number of animals unable to grasp the wire was recorded as a measure of myorelaxation (Bonetti et al., 1982) .
Statistical analysis
All data are expressed as mean Ϯ SEM. When several treatments were compared, one-way ANOVA was used and post hoc comparisons between vehicle-and drug-treated groups were made using Dunnett's multiple comparison test. When two groups were compared, Student's t-test was used. Data from the horizontal wire test were analysed using Fisher's exact test.
Nomenclature
The nomenclature of all molecular targets (receptors, ion channels, enzymes, etc.) cited in this work conforms to the British Journal of Pharmacology's Guide to Receptors and Channels (Alexander et al., 2011) .
Results
Binding studies
Binding studies were used to evaluate whether 2′MeO6MF could displace 3 H]-muscimol binding to rat brain synaptic membranes in a concentration-dependent manner yielding a mean Emax of 219.8 Ϯ 7.6% and apparent EC50 = 20.8 Ϯ 3.7 nM (n = 3 independent experiments). This effect was comparable to diazepam, which also enhanced [ 3 H]-muscimol binding producing an Emax of 276.4 Ϯ 2.5% and an EC50 = 20.4 Ϯ 2.5 nM (n = 3 independent experiments; Supporting Information Figure S1 ).
Electrophysiological studies
Expression of GABA receptors in Xenopus oocytes. Injection of a1/2b2, a1-3,5b1-3g2L and r1 receptor mRNA into Xenopus oocytes resulted in GABA sensitive channels. Increasing concentrations of GABA produced a concentration-dependent increase in the inward whole-cell currents until a maximal response was reached (20-3000 nA).
2ЈMeO6MF is a positive allosteric modulator at a1-containing GABAA receptors Like GABA, 2′MeO6MF did not produce a response when tested against sham-injected oocytes (n = 3; data not shown). When tested alone 2′MeO6MF (300 mM) activated the receptor by <2% of the maximum effect of GABA. In contrast, 2′MeO6MF (300 mM) enhanced the response elicited by a low concentration of GABA (EC 10) in a concentration-dependent manner at recombinant a1b2g2L GABAA receptors expressed in Xenopus oocytes ( Figure 1A) . Interestingly, upon washout, the higher concentrations of 2′MeO6MF produced a rebound current ( Figure 1A ), and this was observed in 60% of cells. This phenomenon has been observed previously with compounds such as mefenamic acid and etomide, and may be due to interactions with residues in the second transmembrane region (Hill-Venning et al., 1997; Halliwell et al., 1999) . In addition, 2′MeO6MF (1-300 mM) enhanced the response elicited by GABA (EC 10) at recombinant a1b1,3g2L and a1b2 GABAA receptors ( Figure 1B ) without any direct activation (data not shown).
Flumazenil (1 and 10 mM) (a competitive benzodiazepine antagonist) did not block the enhancement produced by 2′MeO6MF (100 mM) at a1b2g2L GABA A receptors. At the higher concentration, flumazenil enhanced the effect of GABA by 42%. In contrast, flumazenil (1 and 10 mM) dosedependently attenuated the diazepam-induced enhancement of GABA (10 mM) at this receptor ( Figure 1C ). 2′MeO6MF was most efficacious at a1b2g2L, enhancing GABA responses by 512.1 Ϯ 72%. The efficacy of 2′MeO6MF at a1b1g2L and a1b3g2L receptors was similar, enhancing the effect of GABA by 395.1 Ϯ 53% and 371.1 Ϯ 40.9%. 2′MeO6MF also potentiated GABA EC 10 (1 mM) responses on a1b2 receptor by 502.3 Ϯ 40.9% (Table 1 ). The apparent order of potency of 2′MeO6MF on a1b2 and a1b1-3g2L was a1b2 > a1b3g2L > a1b2g2L > a1b1g2L; however, the differences in EC 50 values were not significant (one-way ANOVA, P > 0.05; n = 4-6).
2ЈMeO6MF directly activates a2b2/3g2L GABAA receptors without any modulatory effects
Oocytes expressing a2b2g2L GABAA receptors responded to 2′MeO6MF at concentrations 10, 30, 100 and 300 mM in the absence of GABA (Figure 2A ). 2′MeO6MF appeared to be a partial agonist producing a maximum response of 70% compared with the current generated by the maximum effect of GABA (3 mM) at this receptor ( Figure 2D and E). In order to evaluate whether 2′MeO6MF also positively modulates a2b2g2L receptors, we studied various concentrations of 2′MeO6MF alone and in the presence of GABA EC 5 (3 mM) and found that the response produced in the presence of GABA was only additive, indicating that 2′MeO6MF does not positively modulate these receptors (Supporting Information Figure S2 ).
At a2b3g2L receptors, 2′MeO6MF directly activated the receptor acting as a full agonist ( Figure 2E ). Although, 2′MeO6MF is apparently more efficacious at a2b3g2L than at a2b2g2L receptors, the difference between potencies of 2′MeO6MF at these receptors was not significant (Table 1 , P < 0.05). 2′MeO6MF also activated a2b2/3 receptors that lacked the g2L-subunit, producing a maximum effect of 22.8 Ϯ 1.5% (at a2b2 receptors) and 42.5 Ϯ 1.3% (at a2b3 receptors) compared with the maximum concentration of GABA (3 mM) ( Table 1 and Figure 2E ). Again the activities did not significantly differ indicating that the g2L-subunit is required for maximum efficacy but is not essential for activity.
The direct activation by 2ЈMeO6MF at a2b2/3g2L GABA A receptors could be attenuated by gabazine, bicuculline and PTZ but not flumazenil
The direct activation of a2b2g2L GABAA receptors by 2′MeO6MF could not be reduced by flumazenil (10 mM; Figure 2B ) despite this concentration inhibiting 60% of the enhancement produced by diazepam (1 mM) ( Figure 2B ). These data infer that 2′MeO6MF does not bind to the classical flumazenil-sensitive benzodiazepine-binding site supporting the binding data. In contrast, the GABAA receptor antagonists, bicuculline and gabazine (SR 95531) attenuated the effect of 2′MeO6MF at a2b2g2L GABAA receptors. Preincubation with bicuculline (10 mM) for 3 min attenuated the activation produced by 2′MeO6MF (100 mM) by 56%. Similarly, gabazine (1 and 10 mM) attenuated the response produced by 2′MeO6MF (100 mM) on a2b2g2L GABAA receptors ( Figure 2C ), by 45 and almost 100%, respectively. Concentration-response curves of 2′MeO6MF in the presence of bicuculline (10 mM) and gabazine (1 mM) showed that this inhibition was non-competitive ( Figure 2D ), despite a fourand fivefold increase in the EC50 for 2′MeO6MF by gabazine and bicuculline, respectively ( Figure 2D ).
PTZ (1 mM) a GABAA receptor blocker (Huang et al., 2001 ) and prototypical anxiogenic drug also attenuated the response produced by 2′MeO6MF (100 mM) by 60% at a2b2g2L GABAA receptors (Supporting Information Figure S3 ).
Figure 1
2′MeO6MF is a positive modulator of a1-containing GABAA receptors expressed in Xenopus oocytes. (A) Representative current trace showing the potentiation of GABA (EC10: 10 mM) by various concentrations of 2′MeO6MF (1, 10, 30, 100 and 300 mM) at human recombinant a1b2g2L GABAA receptors. Horizontal bars show the duration of drug application. In the absence of GABA, 2′MeO6MF (300 mM) produced ª2% of the current produced by the maximum GABA concentration. Note the rebound current following removal of 2′MeO6MF (indicated by the arrows) (B) 2′MeO6MF potentiates the response to GABA (EC10) at recombinant a1b2, a1b1g2, a1b2g2L and a1b3g2L receptors expressed in oocytes. Control GABA concentration at each receptor subtype was 10 mM. Data are mean Ϯ SEM (n = 3-6 oocytes). (C) Representative current trace from an oocyte showing potentiation of GABA (10 mM) by 2′MeO6MF (100 mM) at recombinant a1b2g2L GABAA receptors. As shown, the enhancement of GABA (10 mM) by 2′MeO6MF (100 mM) was not inhibited by flumazenil (1 and 10 mM) whereas potentiation of GABA (10 mM) by diazepam (1 mM) was inhibited by flumazenil (1 and 10 mM). Horizontal bars show the duration of drug application.
2ЈMeO6MF is a potentiator of GABA at a2b1 and a2b1g2L GABA A receptors 2′MeO6MF had little effect in the absence of GABA when evaluated at a2b1g2L GABAA receptors. Instead 2′MeO6MF (1-300 mM) potentiated the effect of a low concentration of GABA (EC10 = 10 mM) at both a2b1 and a2b1g2L GABAA receptors. 2′MeO6MF (300 mM) maximally potentiated ( Figure 3B ) the response to GABA (10 mM) at these receptors. Table 1 summarizes the efficacy and activity of 2′MeO6MF at a2b1 and a2b1g2L GABA A receptors.
Mutating b2-N265S converted 2ЈMeO6MF from an activator to a positive modulator on a2b2g2L GABA A receptors Mutating asparagine to serine at position 265 on the b2 subunit did not inhibit the formation of functional channels when expressed with wild-type a2-and g2L-subunits in oocytes. The maximal concentration of GABA (3 mM) produced currents ranging from 230 to 550 nA. The EC 50 of GABA at a2b2N265Sg2L was 57.7 mM (34.1 to 97.8; 95% CI, n = 4). However, this receptor exhibited a dramatic resistance to the direct activation by 2′MeO6MF. As shown in Figure 3A and B, 2′MeO6MF (300 mM) activated 5-10% of the maximum GABA (3 mM) response at a2b2N265Sg2L receptors. In contrast, 2′MeO6MF (300 mM) potentiated the current response produced by a low concentration of GABA (10 mM) by 454.6 Ϯ 16.3% at the mutant receptor (Figure 3A and B; Table 1 ).
The converse mutation in b1-S265N converts 2ЈMeO6MF from a potentiator to an activator at a2b1S265Ng2L GABA A receptors
In order to confirm that the amino acid residue at position 265 participates in the gating mechanism and is responsible for determining activation versus positive modulation, we generated the converse mutation in the b1-subunit. 2′MeO6MF in the concentration range 1-300 mM directly activated a2b1S265Ng2L recombinant GABA A receptors ( Figure 3C and D) reaching maximal activation at 300 mM (69.4 Ϯ 5.05%), without potentiating the current response elicited by a low concentration of GABA (10 mM) ( Figure 3C ). Figure 3C shows that the effect of 2′MeO6MF (100 mM) in the presence of GABA (10 mM) is additive and not synergistic. In addition the difference between the EC 50 values of 2′MeO6MF at a2b1S265Ng2L and a2b2g2L recombinant GABAA receptors was not significant (n = 4; Student's t-test, P > 0.05) (Table 1) indicating that this amino acid residue participates only in the gating mechanism and as hypothesized is responsible for determining positive modulation versus activation by 2′MeO6MF of a2-containing receptors.
2ЈMeO6MF is inactive at a3/5b1-3g2L and r1 GABA receptors 2′MeO6MF (1-300 mM) did not activate or enhance the response to GABA EC10 at recombinant a3/5b1-3g2L receptors. At a3b2g2L receptors, 2′MeO6MF (100 mM) slightly shifted the GABA dose-response curve to the left. However, this effect was not significant (n = 4, Student's t-test: P > 0.05; (Supporting Information Figure S4A ). At a5b2g2L receptors, 100 mM 2′MeO6MF inhibited responses to high doses (1000-3000 mM) of GABA and shifted the curve slightly to the right; however, this effect was not significant (n = 4, Student's t-test: P > 0.05) (Supporting Information Figure S4B ). 2′MeO6MF (1-100 mM) was found to be inactive at r1 receptors; 2′MeO6MF (100 mM) did not significantly affect the doseresponse curve of GABA at r1 receptors (Supporting Information Figure S4C ). 
95% CI, 95% confidence interval; NE, no effect; Emax, Maximum potentiation produced by 2′MeO6MF relative to GABA EC10. The ability of 2′MeO6MF to directly activate native GABAA channels was examined in hippocampal neurons from the newborn rat. Pharmacological (Caraiscos et al., 2004; Mangan et al., 2005; Herd et al., 2008; Seymour et al., 2009 ) and competitor peptide experiments have shown that these neurons express multiple receptor subtypes including g-and d-containing GABAA channels. Single-channel currents in response to 2′MeO6MF were recorded from inside-out patches pulled from cultured neurons and their characteristics compared with those observed with GABA. All patches were initially held for 5 min to ensure that the patch was electrically silent in the absence of any ligand. A typical example is illustrated in (Supporting Information Figure S5A) showing 2 s of the single-channel trace and an all-points probability histogram measured over 30 s just prior to adding drug. 2′MeO6MF (100 mM) was subsequently flowed across the patch and within 2 min a current with a small average amplitude of 0.7 pA was observed (-Vp = +60 mV, Supporting Information Figure S5B ). With time, however, the average current amplitude increased (Supporting Information Figure S5C , 2.7 pA), typical of native GABAA channels, and within approximately 5 min the average amplitude had reached a maximum of 4.1 pA (Supporting Information Figure S5D ). The current displayed all the hallmarks of an outwardly rectifying GABAA current (Curmi et al., 1993) ; the open probability was noticeably lower and the current amplitude was reduced at -Vp = -60 mV compared with -Vp = +60 mV; compare single-channel traces and all-points probability histograms in Supporting Information Figure S5D , E. With near equimolar Cl -solutions in the bath and pipette and stepping the holding potential to 0 mV the current was negligible, consistent with it being carried by Cl -ions (Supporting Information Figure S5F ). In five other patches where 2′MeO6MF (100 mM) was applied similar Cl -currents were activated, consistent with these being mediated by GABAA channels -see Supporting Information Figure S5 . In 13 additional patches no response to the drug was observed. 5 mM) in the presence of diazepam (1 mM) and this effect was attenuated by flumazenil (10 mM) at a2b2g2L GABAA receptors. In contrast, the direct activation of 2′MeO6MF (30 mM) on the same receptor was not attenuated by flumazenil (10 mM). (C) Representative trace showing that a 3 min pre-incubation with bicuculline (10 mM) attenuates the response produced by 2′MeO6MF (100 mM) by 56 Ϯ 4% at a2b2g2L GABAA receptors. Gabazine (10 mM and 100 mM) also attenuated the response produced by 2′MeO6MF on a2b2g2L GABAA receptors by 45 Ϯ 4% and 100% respectively. (D) Concentration-response curves for 2′MeO6MF alone and 2′MeO6MF in the presence of bicuculline (10 mM) and gabazine (1 mM) at a2b2g2L GABAA receptors expressed in Xenopus oocytes. Data are mean Ϯ SEM (n = 4-6 oocytes). (E) Concentration-response curves for 2′MeO6MF on a2b3g2L, a2b2g2L, a2b3 and a2b2 recombinant GABAA receptors expressed in oocytes. Currents are expressed as a percentage of the peak current elicited by 3 mM GABA. Data are mean Ϯ SEM (n = 4-6 oocytes).
Although the absolute composition of native GABAA channels is still not known, they can be classified into g-or d-containing receptors. Both receptor subtypes are able to transition to high conductance states in response to drugs as a consequence of inter-receptor protein interactions Seymour et al., 2009) . Competitor peptides, which mimic this receptor-protein binding site and correspond to the unique amino acid sequence for the amphipathic intracellular helix (MA helix) of either the g2-or d-subunit, significantly reduce the current mediated by their respective channel subtypes Seymour et al., 2009 ). On inside-out patches displaying large amplitude currents in response to 2′MeO6MF (100 mM) a peptide mimicking the g2 MA helix [g(381-403) MA peptide] was subsequently applied in the continued presence of the drug. In the example shown in Figure 4 2′MeO6MF (100 mM) activated a current with an average amplitude of 2.7 pA (-Vp = +60 mV). Upon addition of 1 mM, g2 MA peptide currents with smaller amplitudes and briefer opening times appeared in the recording, typical of competitor peptide. The 2 s single-channel trace illustrates the variable nature of the current whereas the expanded trace shows the range of multiple current amplitudes observed. The all-points probability histogram along side reveals the current distribution over a longer time period (30 s) with average peaks at 1.2 and 2.8 pA. In all three patches where the g MA peptide was applied (1 mM) a similar effect on current amplitude was observed indicating that 2′MeO6MF (100 mM) directly activated currents mediated by native g-containing GABA A channels.
In vivo studies
Effects on general behaviour and acute toxicity in mice. 2′MeO6MF was tested at doses 1, 10 and 100 mg·kg -1 . Overt behavioural effects were observed for each mouse at 0, 30 and 60 min, 24, 48 and 72 h and 1 week after injection. No overt acute toxicity was observed at any time point as judged from the observed lack of convulsions respiratory distress (cyanosis, gasping), writhing, changes to reflex activity or mortality. An increase in spontaneous activity and escape behaviour was observed at doses of 1 and 10 mg·kg -1 in three out of five animals after 30 and 60 min of injection. Also an increased hypersensitivity (measured as increased irritability and aggressiveness during handling) and increase in escape behaviour was observed in the same animals. At 100 mg·kg -1 , four out of five animals appeared slightly drowsy (general observation); however, the righting reflex was not lost. At 24 h to 1 week after injection all animals seemed well with no observable changes in behaviour, spontaneous activity or appearance. 
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Elevated plus maze test
Results from the ANOVA analysis showed that both the diazepam-and 2′MeO6MF-treated animals displayed significantly different effects from the vehicle controls in both the % number of open-arm entries and % time spent in the open arms [F(6,49) = 29.1 P < 0.001 and F(6,49) = 24.7 P < 0.001 respectively]. Dunnett's post hoc test revealed that diazepam at doses of 1 and 2 mg·kg -1 caused a significant increase in these two parameters compared with vehicle. 2′MeO6MF at doses of 1, 10, 30 and 100 mg·kg -1 also induced an anxiolytic effect as evidenced in the increase of % open-arm entries and % time spent in the open arms ( Figure 5A and B). 2′MeO6MF did not significantly influence the number of entries into the closed arms suggesting that the anxiolytic effects observed at these doses was not due to an increase in the exploratory activity [F(6,49) = 0.33 P > 0.05]. However, at the higher doses, 2′MeO6MF (30 and 100 mg·kg -1 ) had a tendency to reduce the number of closed arm entries compared with the vehicle (Supporting Information Figure S6 ). The reduction in both the open and closed arm entries at high doses may indicate the onset of sedative effects.
PTZ but not flumazenil reversed the anxiolytic effect of 2ЈMeO6MF in the elevated plus maze test
Co-administration of 2′MeO6MF (10 mg·kg -1 ) with flumazenil (2.5 mg·kg 
Light/dark box test
ANOVA showed a significant difference between groups in the time spent in the lit compartment [F(6,49) = 27.7 P < 0.001] and in the number of transitions between lit and dark compartments [F(6,49) = 4.87 P < 0.001, respectively]. Dunnet's post hoc analysis revealed that diazepam at doses of 1 and 2 mg·kg -1 significantly (P < 0.01) increased the time spent in the lit compartment and the number of transitions between the compartments, indicating anxiolytic activity and validating our paradigm. Similarly, 2′MeO6MF at doses of 1 and 10 mg·kg -1 significantly (P < 0.01) increased the % of time spent in the lit area and the number of transitions between areas. Higher doses (30 and 100 mg·kg -1 ) were ineffective (Figure 6Ai , Aii).
Holeboard test
The influence of treatment on the number of head dips [F(6,49) = 6.16 P < 0.001] and the total time spend head dipping reached significance [F(6,49) = 6.16 P < 0.001]. Administration of 2 mg·kg -1 diazepam significantly decreased the number of head dips and both 1 and 2 mg·kg -1 diazepam decreased the total time spent head dipping. In contrast, low doses of 2′MeO6MF (1 and 10 mg·kg -1 ) did not significantly decrease the number of head dips or time spent head dipping (P > 0.05). However, at higher doses of 2′MeO6MF (30 and 100 mg·kg -1 ), there was a significant decrease in the number of head dips and total time spent in head dipping. These results demonstrate that 2′MeO6MF has sedative effects at higher doses but not at lower doses (Figure 6Bi and ii).
Measurement of locomotor activity
Locomotor activity results are shown in Figure 6C . ANOVA revealed a significant difference between means [F(6,49) = 22.02 P < 0.001]. Dunnett's post hoc comparison test showed a significant decrease (P < 0.01) in the number of beam breaks induced by diazepam at doses 1 and 2 mg·kg -1 . 2′MeO6MF at doses 30 and 100 mg·kg -1 also significantly (P < 0.01) decreased the number of beam breaks; however, doses 1 and 10 mg·kg -1 did not produce any changes in this parameter again demonstrating the lack of sedative effect at these lower doses.
Horizontal wire test
The results from the horizontal wire test are shown in the Table 2 . Neither diazepam (1 mg·kg -1 ) nor 2′MeO6MF (1-100 mg·kg -1 ) compromised the grasping of wire when compared with vehicle controls pointing to a lack of myorelaxation at these dosages. Diazepam at 3 and 10 mg·kg -1 , i.p., in contrast, elicited significant myorelaxation in mice (P < 0.01, P < 0.001, Fisher's exact tests) ( Table 2) 2′MeO6MF directly activates g-containing GABAA channels in hippocampal neurons. (A) In an excised inside-out patch 100 mM 2′MeO6MF activated a current with a maximum average amplitude of 2.8 pA (-Vp = -60 mV). (B) With the addition of 1 mM g2(381-403) MA peptide, there was a reduction in the current amplitude. Lower amplitudes of around 1.2 pA were now visible in the recording as depicted in (B) and both the reduction in open probability (increase in the zero peak) and current amplitude are reflected in the 30 s all-points probability histogram alongside.
Thiopental-induced loss of righting reflex
One-way ANOVA followed post hoc Dunnett's multiple comparison test showed that diazepam at doses 1 and 2 mg·kg -1 significantly (P < 0.01) increased the duration of loss of righting reflex. Similarly, 2′MeO6MF at doses of 30 and 100 mg·kg -1 significantly (P < 0.05 and P < 0.01, respectively) increased the duration of loss of righting reflex; however, doses 1 and 10 mg·kg -1 did not significantly affect (P > 0.05) this parameter (Table 3) .
Discussion
Recent behavioural studies have shown that the anxiolytic and sedative effects of diazepam are mediated by the a1/2-containing GABAA receptors, respectively (Atack, 2010a) . Thus agents selective for GABAA receptors containing either a1/2-subunits would be useful sedative and/or anxiolytic agents. In this study, we investigated the ability of a synthetic flavone, 2′MeO6MF to activate or modulate various a-and ), n = 8 per group. *P < 0.05, **P < 0.01 indicate significance from control using one-way ANOVA followed by Dunnett's post hoc test. Co-application of flumazenil (Flu; 2.5 mg·kg ) or vehicle (VEH). Columns represent mean Ϯ SEM (n = 8 per group). *P < 0.05, **P < 0.01 or ***P < 0.001 compared with vehicle group using ANOVA followed by Dunnett's multiple comparison test.
b-containing GABAA receptors expressed in Xenopus oocytes. The results indicate that 2′MeO6MF differentially affects GABAA receptor subtypes.
2′MeO6MF was found to directly activate a2b2/3 and a2b2/3g2L receptor subtypes without modulating the effect of GABA. Activation by 2′MeO6MF was attenuated by bicuculline and gabazine, but not flumazenil, a result similar to that observed with bicuculline attenuating the direct effect of etomidate (Belelli et al., 1997) .
Interestingly, replacing the b2/3 with the b1 isoform in a2-containing receptors markedly changed the activation barrier. Instead of activating the receptor, 2′MeO6MF positively modulated a2b1 and a2b1g2L receptors indicating that the activation and modulation properties of 2′MeO6MF at a2-containing receptors are distinct and dependent on the type of b-subunit present. Several drugs are known to display greater efficacy at b2/3-over b1-containing receptors including the general anaesthetic etomidate and sedative anticon-
Figure 6
Effect of diazepam (1 and 2 mg·kg -1 ) and 2′MeO6MF (1-100 mg·kg Columns represent mean Ϯ SEM (n = 8/group). *P < 0.05, **P < 0.01 compared with vehicle group, one-way ANOVA followed by Dunnett's multiple comparison test.
vulsant loreclezole (Hill-Venning et al., 1997) . Subsequent studies found that a single asparagine (N) residue located at position 265 on the second transmembrane domain of the b2 subunit (and equivalent position at b3) conferred this selectivity (Desai et al., 2009) . When b2N265 is mutated to serine (S), the homologous amino acid in the b1 subunit, the ability of etomidate and loreclezole to potentiate GABA currents and the direct activation by etomidate is diminished . Accordingly, knock-in mice carrying either b2N265S or b3N265M mutation display impaired sensitivity to the in vivo actions of these drugs (Groves et al., 2006) . Interestingly, when N265 of the b2 subunit was mutated to serine to mimic the b1 residue at the equivalent position, 2′MeO6MF changed from an activator to a modulator at the a2-containing mutant receptor. At a2-containing receptors containing the converse mutant subunit b1S265N, 2′MeO6MF was converted from a modulator to a direct activator. Interestingly, this same mutation has also been shown to induce direct currents at a1b1S265Ng2L by mefanamic acid (Halliwell et al., 1999) .
As the activation by 2′MeO6MF was significantly diminished on a2b2N265Sg2L receptors, but had positive modulation at a similar concentration range; this suggests that the modulation and direct activation by 2′MeO6MF are mediated via a single binding site, but that there are two distinct energy barriers. It is proposed that serine can strongly hydrogenbond via its hydroxyl moiety to stabilize the closed state. Thus 2′MeO6MF requires GABA to help shift the equilibrium from the closed to the open state. In contrast, the hydrogen bond formed by the amide group of asparagine is weaker and the energy required to shift the equilibrium of the channel from the closed to the open state is less. Thus, 2′MeO6MF opens the channel without the aid of GABA. Therefore, the amino acid at position b265 appears to contribute to the activation pathway, enabling 2′MeO6MF to go from an activator to a modulator and vice versa at a2-containing receptors. However, as we did not identify the binding site for 2′MeO6MF, we cannot rule out the possibility that there may be more than one binding site for 2′MeO6MF on these receptors.
In contrast, the effects of 2′MeO6MF on a1-containing-GABA A receptors were non-selective. 2′MeO6MF positively modulated all a1b2 and, a1b1-3g2L receptor subtypes, but did not directly activate them, indicating the importance of the a-subunit in the gating mechanism. 2′MeO6MF did not activate or potentiate a3/5b1-3g2L subtypes. Thus unlike other flavonoids, 2′MeO6MF selectively affects a1/2-containing GABA A receptors, and, unlike barbiturates and neurosteroids that non-selectively modulate and directly activate most GABAA receptor subtypes (Lambert et al., 1996; Thompson et al., 1996; Maitra and Reynolds, 1998) , the potentiation and direct activation of 2′MeO6MF are subtype specific.
While recombinant studies revealed that 2′MeO6MF could differentiate between various GABA A receptor subtypes, ex vivo studies in neuronal cells were conducted to confirm that 2′MeO6MF could indeed activate native g2-containing GABA A channels. Because native g-containing GABAA receptors are involved in receptor-protein interactions that affect their ion permeation Seymour et al., 2009) , the disruption of these interactions, using g2-subunitspecific competitor peptides, enables the underlying receptor's identity to be revealed. 2′MeO6MF directly activated a Cl -current in hippocampal pyramidal neurons that exhibited all the hallmarks of those mediated by GABAA channels (Eghbali et al., 1997; Seymour et al., 2009) . The reduction in current activity upon application of the g2 MA peptide confirmed that this current was indeed mediated by g2-containing GABA A channels. The subtype-specific direct activation of 2′MeO6MF described in the recombinant system together with the activation of native g-containing GABAA channels suggest that a2b2/3g2 receptors may underlie the drug's activation in these neurons. , i.p.) and 2′MeO6MF (1, 10, 30 and 100 mg·kg -1 , i.p.). *P < 0.05, **P < 0.01 significantly different from vehicle: one-way ANOVA followed by Dunnett post hoc multiple comparison test (n = 8 per group). Recent behavioural studies have shown that the anxiolytic action of benzodiazepines is largely mediated by a2/3-containing GABAA receptors, suggesting that these subunits could be useful targets for the development of novel nonsedative anxiolytic agents (Low et al., 2000; Atack, 2010a) . In order to correlate the in vitro with the in vivo effects, 2′MeO6MF was subjected to a battery of behavioural studies in mice. Like diazepam, 2′MeO6MF at doses ranging from 1 to 100 mg·kg -1 induced anxiolytic effects in two unconditional models of anxiety: the elevated plus maze and light/dark box tests. 2′MeO6MF exerted dual effects in these anxiety paradigms. In the elevated plus maze, low doses of 2′MeO6MF (1 and 10 mg·kg -1 ) showed anxiolytic effects, whereas at higher doses (30 and 100 mg·kg -1 ), the anxiolytic effects were reduced possibly indicating sedative effects. Like the in vitro data, the anxiolytic effects of 2′MeO6MF were not blocked by the benzodiazepine antagonist, flumazenil but were attenuated by the GABAA channel blocker, PTZ. These data infer that the anxiolytic effects are mediated via the GABAergic system but not through the classical benzodiazepine site despite 2′MeO6MF weakly displacing flunitrazepam binding (Kahnberg et al., 2002) . These data indicate that 2′MeO6MF binds to a novel as yet unidentified site on a2b2/3g2L GABAA receptors.
A similar pattern was observed in the light/dark box test, 1 and 10 mg·kg -1 of 2′MeO6MF produced an increased anxiolytic effect whereas 30 and 100 mg·kg -1 were ineffective, suggesting that at high doses, a1-mediated sedation might have led to a decrease in the anxiolytic activity (Rudolph et al., 1999) . Similarly, 2′MeO6MF at doses 30 and 100 mg·kg -1 decreased exploratory parameters in the holeboard and spontaneous locomotor activity. Furthermore, at 100 mg·kg -1 , 2′MeO6MF significantly potentiated the central depressant action of the barbiturate sodium thiopental, confirming that 2′MeO6MF acts as an anxiolytic at low doses and a sedative at high doses. In addition, 2′MeO6MF showed no effects in the horizontal wire test at all doses tested indicating no myorelaxant effects.
In contrast, diazepam at doses 1 and 2 mg·kg -1 decreased time spent in head dipping but only the higher dose of diazepam decreased the number of head dips in the holeboard test. Diazepam at the doses tested also decreased spontaneous locomotor activity, increased the duration of loss of righting reflex in the thiopental-induced sleep time and impaired the ability of mice to grasp the horizontal wire demonstrating sedative and myorelaxant effects at the doses tested. Classical benzodiazepines indiscriminately modulate GABAA receptors containing the a1-3/5-subunits and are regarded as relatively non-selective modulators (Atack et al., 2005; Whiting, 2006) . Our results and those of others (Rudolph et al., 1999) showed that the administration of diazepam to animals leads to a series of pharmacological actions within a narrow dose range.
Interestingly, 2′MeO6MF at doses as low as 1 mg·kg -1 is as effective as diazepam (1 mg·kg -1 ) as an anxiolytic agent in vivo. Given that 2′MeO6MF is approximately 100-to 1000-fold weaker at activating GABAA receptors than diazepam, the enhanced in vivo effect of 2′MeO6MF may be that other as yet untested receptors or enzymes are involved in its activity. Indeed it has been shown that the anxiolytic effects of neurosteroids are eliminated in d-knock-out mice (Mihalek et al., 1999) implicating the d-subunit in anxiety. In addition it has been shown that PKCe regulates anxiety effects mediated via the GABA A receptor (Hodge et al., 2002) . Given that retrochalcones (a class of molecules related to flavonoids) and flavonoids themselves can modulate d-containing GABAA receptors (Jiang et al., 2011) and PKC enzymes (Gamet-Payrastre et al., 1999) , respectively, it may be that 2′MeO6MF acts at d-containing GABAA receptors and or modulates PKCe activity. However, the involvement of these and other possible targets is yet to be determined. Furthermore, unlike diazepam, 2′MeO6MF does not require GABA to mediate its effects, acting preferentially as an allosteric activator at the a2b2/3g2L receptors rather than as a positive modulator and this may also be contributing to its enhanced in vivo activity.
2′MeO6MF, despite modulating the a1-containing receptors, showed clear segregation of sedative and anxiolytic doses, suggesting that its direct actions on a2-containing receptors are more effective than its modulatory actions on a1-containing receptors. It is also important to note that not all compounds conform to the hypothesis that the a1-subunit mediates sedation and that high efficacy at this subtype is accompanied by sedation (Lippa et al., 2005; Popik et al., 2006) . While the reason for the lack of sedation in these compounds is unclear, at the very least, the data suggest that efficacy as measured in recombinant a1-containing GABAA receptors may not necessarily be predictive of sedative liability (Popik et al., 2006) .
The myorelaxant effects mediated by diazepam have been shown to be mediated by a2-containing receptors although a3-and a5-containing receptors are also involved (Crestani et al., 2001; . In this study, 2′MeO6MF, but not diazepam, failed to exert myorelaxant effects. A number of agents lack myorelaxant effects despite selective effects for a2-containing GABAA receptors (Fernandez et al., 2008) . The reasons why 2′MeO6MF and other a2-selective agents do not exert myorelaxant effects is not yet understood. It is possible that the myorelaxant effects are mediated by a3/5-containing receptors and 2′MeO6MF lacks activity at these receptors. It may be that 2′MeO6MF is acting at other subtypes such as a4/6b1-3g2L, d-containing GABAA receptors and or nonGABAergic targets to counteract the effect. Interestingly, a recent study showed that limiting activity at b1-containing GABAA receptors reduces ataxia (Gee et al., 2010) . As 2′MeO6MF has limited effects on b1-containing a1/a2 GABAA receptors, the reduced activity at these receptors may also be a contributing factor to the lack of myorelaxant effects.
In summary, 2′MeO6MF positively modulated all a1-containing and a2b1g2L while it directly activated a2b2/3 and a2b2/3g2L GABAA receptors. Behavioural studies revealed that 2′MeO6MF exerts anxiolytic effects at low doses and sedative effects at high doses without myorelaxant effects. Due to its differential effects on GABAA receptor subtypes, 2′MeO6MF can serve as a tool to study the complex mechanisms of activation and modulation of these receptors, and highlights another potential site on GABAA receptors. It is envisaged that the mechanism of direct activation by flavonoids such as 2′MeO6MF on both recombinant and native systems will emerge as an area of interest and may help in understanding how such activation is produced by barbiturates and steroids. Figure S2 Example of a trace from an oocyte expressing human recombinant a2b2g2L receptors. 2′MeO6MF (30 mM) and a submaximal concentration of GABA (EC 10 10 mM) activated the receptor (duration indicated by open and black bars respectively). When 2′MeO6MF (30 mM) and GABA (10 mM) are applied together, the resultant peak current (735 nA) is approximately the sum of the individual currents 550 nA (2′MeO6MF 30 mM) and 165 nA (GABA 10 mM). Figure S3 Recording from a2b2g2L GABA A receptors expressed in Xenopus oocytes showing PTZ (1 mM) blocking the effect of 2′MeO6MF (100 mM). Horizontal bars indicate duration of drug application. Figure S4 Concentration-response curves for GABA alone () and GABA in the presence of 100 mM 2′MeO6MF (᭡) on (A) a3b2g2L; (B) a5b2g2L; and (C) r1 GABA receptors. Data are expressed as mean Ϯ SEM (n = 4-5 oocytes). ) on the number of closed arm entries of the elevated plus maze over a 5 min test period in the mice. Each bar represents mean Ϯ SEM (F = 0.33 P > 0.05 ANOVA followed by Dunnet's post hoc test).
Scheme 1
Synthesis of 2′-methoxy-6-methylflavone (2′MeO6MF).
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